NCT07469007Recruiting
Impact of Surgery for Deep Posterior Endometriosis on Ovarian Reserve (ENDORO)
Impact of Surgery for Deep Posterior Endometriosis on Ovarian Reserve
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
Endometriosis is a chronic condition typically affecting women of reproductive age and often responsible for chronic pelvic pain and/or infertility. Its prevalence is estimated at 10% of the female population. Deep endometriosis is a specific phenotype of the disease, defined histologically by infiltration of the peritoneum exceeding 5 mm or by fibromuscular plaques infiltrating the muscularis propria of the abdominopelvic organs. It affects approximately 12 to 20% of patients with endometriosis. Surgery is one of the treatment options. Its aim is anatomical restoration, notably through complete macroscopic resection of the lesions and the release of adhesions, particularly those affecting the adnexa. While the negative impact of cystectomies on ovarian reserve is well known, the impact of surgery for severe deep endometriosis without ovarian involvement has never been studied. Yet, these procedures are regularly performed, and in the vast majority of cases on women of reproductive age. Moreover, the impression gathered in routine practice suggests a decrease in reserve parameters of around 5%. Therefore, understanding the actual impact of the procedure on ovarian reserve would, if it were concrete, allow for expanding the indications for preoperative fertility preservation to this subgroup of patients. The main objective is to evaluate the impact of complete macroscopic resection of severe deep posterior pelvic endometriosis on the change in AMH levels at 12 months compared to an unexposed group.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 9 Mar 2026
- Start date
- 11 Feb 2025
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
- Diseases
- Endometriosis
- NCT number
- NCT07469007
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 11 Feb 2025 to the primary completion date, 1 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of GnRH agonist therapy at or within the preceding 3 months of enrollment;
Other illness
- History of surgery for severe deep endometriosis;
Lab values
- Severe preoperative premature ovarian insufficiency (defined by AMH \<1ng/mL and antral follicle count \<8);
Other
- Presence of ovarian involvement defined by the presence of at least one endometrioma \>5 mm;
- BMI \>35 kg/m²;
- Menopausal status;
- Patient participating in another trial with an exclusion period that has not yet expired at the time of screening;
- Protected patient: adult under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision;
- Pregnant, breastfeeding, or postpartum woman.
Who the study is looking for
- Female, aged 18 to 39 years old;
- Suspected severe deep posterior pelvic endometriosis on reference pelvic MRI (ovarian kissing, obliteration of the pouch of Douglas) with concordant clinical examination, or confirmed severe deep posterior pelvic endometriosis during exploratory laparoscopy;
- Patient affiliated with or covered by a social security plan;
- Patient having been informed and having given her free, informed, and written consent
Age in the registry: 18 years to 39 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinique La Croix Du Sud Coordinator of this site? Confirm its status | Quint-Fonsegrives | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.